CONTENTS

Preface xv
Acknowledgements xvii
Disclaimer xix

1 Antipsychotic Drugs 1
   Introduction 1
   Pharmacology 1
      Chemistry 2
      Mechanism of Action 3
      Pharmacokinetics 3
   Indications for Use of Antipsychotic Drugs 4
   Drug Selection and Initiation of Treatment 7
      Drug Selection for the Treatment of Schizophrenia 7
      Effects of Antipsychotic Agents on Symptoms of Schizophrenia 15
      Drug Selection for the Treatment of Bipolar Disorder 19
      Drug Selection for the Treatment of Major Depression With Psychotic Features 19
      Drug Selection for the Treatment of Delusional Disorder 20
      Drug Selection for the Treatment of Delirium 20
      Drug Selection for the Treatment of Psychosis and Agitation Associated with Dementia 21
      Drug Selection for the Treatment of Mental Retardation and Developmental Disorders 21
      Drug Selection for Huntington’s Disease and Tourette’s Disorder 22
      Substance-induced Psychoses 22
      Adverse Effects of Antipsychotics 23
      Acute Extrapyramidal Side Effects (Dystonia, Parkinsonism, Akathisia) 25
<table>
<thead>
<tr>
<th>CONTENTS</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Tardive Dyskinesia and Other Tardive Syndromes</td>
<td>26</td>
</tr>
<tr>
<td>Neuroleptic Malignant Syndrome</td>
<td>29</td>
</tr>
<tr>
<td>Endocrine and Sexual Effects</td>
<td>30</td>
</tr>
<tr>
<td>Metabolic Effects</td>
<td>31</td>
</tr>
<tr>
<td>Cardiovascular Effects</td>
<td>32</td>
</tr>
<tr>
<td>Gastrointestinal Effects</td>
<td>34</td>
</tr>
<tr>
<td>Hepatic Effects</td>
<td>34</td>
</tr>
<tr>
<td>Hematological Effects</td>
<td>34</td>
</tr>
<tr>
<td>Other Side Effects</td>
<td>35</td>
</tr>
<tr>
<td>Drug Interactions and Antipsychotic Agents</td>
<td>36</td>
</tr>
<tr>
<td>Antipsychotic Medications and Pregnancy</td>
<td>38</td>
</tr>
<tr>
<td>Additional Reading</td>
<td>39</td>
</tr>
</tbody>
</table>

### 2 Antidepressants

<table>
<thead>
<tr>
<th>CONTENTS</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>41</td>
</tr>
<tr>
<td>Pharmacology</td>
<td>41</td>
</tr>
<tr>
<td>Mechanisms of Action</td>
<td>42</td>
</tr>
<tr>
<td>Pharmacokinetics</td>
<td>44</td>
</tr>
<tr>
<td>Indications for Use of Antidepressants</td>
<td>49</td>
</tr>
<tr>
<td>Panic Disorder (PD)</td>
<td>50</td>
</tr>
<tr>
<td>Obsessive–Compulsive Disorder (OCD)</td>
<td>50</td>
</tr>
<tr>
<td>Generalized Anxiety Disorder (GAD)</td>
<td>50</td>
</tr>
<tr>
<td>Social Phobias and Posttraumatic Stress Disorder (PTSD)</td>
<td>50</td>
</tr>
<tr>
<td>Bulimia</td>
<td>51</td>
</tr>
<tr>
<td>Anorexia Nervosa</td>
<td>51</td>
</tr>
<tr>
<td>Body Dysmorphic Disorder (BDD)</td>
<td>51</td>
</tr>
<tr>
<td>Premenstrual Dysphoria (PMDD)</td>
<td>51</td>
</tr>
<tr>
<td>Childhood Disorders</td>
<td>52</td>
</tr>
<tr>
<td>Other Psychiatric Disorders</td>
<td>52</td>
</tr>
<tr>
<td>Other Medical Conditions</td>
<td>53</td>
</tr>
<tr>
<td>Drug Selection and Initiation of Treatment for Major Depression</td>
<td>55</td>
</tr>
<tr>
<td>Special Considerations in the Selection of an Antidepressant</td>
<td>56</td>
</tr>
<tr>
<td>Initiation of Treatment</td>
<td>58</td>
</tr>
<tr>
<td>Therapeutic Drug Monitoring</td>
<td>58</td>
</tr>
<tr>
<td>Early, or Pre-response, Period</td>
<td>62</td>
</tr>
<tr>
<td>Response, or Acute Treatment, Period</td>
<td>63</td>
</tr>
</tbody>
</table>
Treatment of Partially Responsive and Nonresponsive Patients 63
Antidepressant Augmentation 63
Changing to a New Agent 66
Continuation and Maintenance Periods, and Discontinuation 67
Side Effects 69
   Anticholinergic Effects 70
   Autonomic Effects 70
   Neurologic Effects 72
   Weight Gain 73
   Gastrointestinal Symptoms 73
   Sexual Dysfunction 73
   Cardiac Conduction 74
   Suicide Risk 74
   Allergic and Hematologic Effects 75
   Other Effects 75
   Central Serotonergic Syndrome 75
   Monoamine Oxidase Inhibitors 75
Drug Interactions 76
   Tricyclic Antidepressants 76
   Pharmacokinetic Effects 77
   Monoamine Oxidase Inhibitors 78
   Serotonin Reuptake Inhibitors 78
   Other Second-Generation Antidepressants 79
   Third-Generation Antidepressants 79
Summary 79
   Recommendations for the Use of Antidepressants 80
Additional Reading 80

3 Mood Stabilizers 83
Introduction 83
Pharmacology 85
   Chemistry 85
   Mechanism of Action 85
   Pharmacokinetics 87
Indications 90
Drug Selection and Initiation of Treatment 90
   Acute Mania 90
   Drug Selection 90
5 Sedative–Hypnotic Agents 155
   Introduction 155
   Diagnosis 155
   Treatment Options 156
   Non-prescription Agents 157
   Prescription Medications 158
   Pharmacology 159
      Benzodiazepines 159
      Chlora Hydrate 159
      Zolpidem 160
      Zaleplon 160
      Eszopiclone 160
      Ramelteon 161
   Drug Selection 161
      Other Prescription Hypnotics 164
   Treatment Implementation 166
   Adverse Effects 167
      Benzodiazepines 167
      Chlora Hydrate 168
      Zolpidem 168
      Zaleplon 169
      Eszopiclone 169
      Ramelteon 169
   Drug Interactions and Special Precautions 170
   Summary 172
   Additional Reading 172

6 Psychostimulants 175
   Introduction 175
   Pharmacology 175
      Chemistry 175
      Mechanism of Action 176
      Pharmacokinetics 177
      Indications and Contraindications 180
   Drug Selection 180
   Treatment Initiation and Dose Titration 183
      Treatment Evaluation 185
      Maintenance Treatment 187
      Treatment Resistance 187
      Effects of Treatment on Symptoms 188
ADHD in Adults 189
Alternative Preparations to the Standard Stimulant Medications 189
Narcolepsy 190
Other Indications 193
Costs 193
Adverse Effects 193
Drug Interactions 196
Summary 197
Additional Reading 198

7 Cognitive Enhancers and Treatments for Alzheimer’s Disease 199
Introduction 199
Pharmacology 199
  Mechanism of Action 199
  Pharmacokinetics 203
Indications 205
Drug Selection 205
Treatment Initiation 206
  Maintenance Treatment 207
  Treatment Evaluation 208
Adverse Effects 209
  Cholinesterase Inhibitors 209
Drug Interactions 211
Summary 212
Additional Reading 213

8 Drugs for Treating Substance Abuse Disorders 215
Introduction 215
Syndromes Associated with Intoxication 216
  Alcohol Intoxication 216
  Sedative–Hypnotic Intoxication 217
  Opiate Intoxication 218
  Cocaine and Amphetamine Intoxication 219
  Intoxication by LSD, Mescaline, MDMA (‘Ecstasy’), and Psilocybin 220
  Phencyclidine Intoxication 221
Drug Treatment of Withdrawal Syndromes 222
  Alcohol Withdrawal 223
Contents

Withdrawal from Sedative–Hypnotics 230
Withdrawal from Opiates 233
Management of Withdrawal in Patients with Multiple Dependencies 237
Agents to Aid Relapse Prevention 237
Medications for Alcohol Dependence 238
Medications for Cocaine Dependence 241
Medications for Opiate Dependence 242
Special Considerations 247
Drug Treatments for Nicotine Dependence 247
Pharmacotherapies for Substance Abusers with Additional Psychiatric Illness 248
Pharmacotherapy for Specific Psychiatric Disorders 249
Drug Interactions in Chemical Dependency 251
Additional Reading 252

Index 255